Regulators and standards body concur that a single HPLC test cannot confirm peptide identity, requiring at least two orthogonal methods
Executive summary: A regulator and a standards body jointly agreed that a single HPLC result is not enough to confirm a research peptide's identity; at least two orthogonal identification procedures are required. The decision raises the analytical bar for peptide research, likely increasing testing complexity, cost, and timelines for labs and drug developers.
Who is involved: Unnamed regulator, unnamed standards body, Oath Research (analysis provider), peptide researchers and analytical laboratories.
Likely next: Expect updated guidance or standards reflecting the multi‑method requirement, with labs adopting additional orthogonal techniques such as mass spectrometry or NMR.
Regulators and an independent standards body have each concluded that a single high‑performance liquid chromatography (HPLC) result cannot be used to confirm the identity of a research peptide. Their agreement follows an analysis by Oath Research that showed reliance on HPLC retention time alone is insufficient for unambiguous peptide identification. The authorities therefore recommend that at least two orthogonal analytical procedures be applied before a peptide can be regarded as fully characterized. For laboratories engaged in peptide synthesis or testing, the new expectation will likely raise the analytical workload and associated costs, as teams will need to supplement HPLC with complementary techniques such as mass spectrometry, nuclear magnetic resonance, or peptide mapping. Regulatory submissions that previously relied on a single HPLC profile may now require additional data packages, potentially lengthening review timelines. In the near term, we can expect a gradual shift in standard operating procedures toward multi‑method workflows, which may also create demand for integrated analytical platforms and for service providers that offer orthogonal peptide verification.
What's next — scenarios
Regulatory Mandate Implementation (60%)
Increased CAPEX for peptide labs due to procurement of MS or NMR equipment.
- Official guidance update from FDA/EMA regarding peptide identity
- Adoption of new GMP standards for peptide analytical validation
Operational Bottleneck & Delay (25%)
Extended drug development timelines and increased cost-per-batch for peptide therapeutics.
- Increase in regulatory queries/rejections based on insufficient characterization
- Significant slowdown in peptide-based IND applications
Analytical Service Expansion (15%)
Market growth for CROs specializing in integrated multi-method peptide characterization.
- Surge in outsourcing volume for orthogonal peptide testing
- New product launches for integrated HPLC-MS analytical platforms
What to watch
- Release of formal regulatory guidance update (Next 90 days)
- Q3/Q4 earnings reports from major analytical instrument manufacturers (Next 60 days)
- Survey data on CRO pricing for orthogonal peptide verification (Next 90 days)
Timeline
- — Regulator and standards body independently agree: one HPLC result isn't enough, Oath Research analysis finds (PR Newswire)